Login to Your Account



Clinic Roundup


Tuesday, August 2, 2011
Alnylam Pharmaceuticals Inc., of Cambridge, Mass., completed a Phase I trial of ALN-VSP, an RNAi therapeutic for solid tumors with liver involvement.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription